| This week's sponsor is Premier Research. | | | A Brand New Day for Rare Cancer Study
As cancer's molecular origins emerge and researchers join forces, it's a new day for study of rare oncology. Read our white paper for patient viewpoints and trends in trial design, regulation, and legislation. Premier Research. It's what we do. Best. |
Top Stories Tuesday, December 13, 2016 New York City has always lagged behind the big life sciences cities in Massachusetts and California, predominantly because of a lack of space, but it has over the years pushed for greater investment, and today New York Mayor Bill de Blasio has launched a new $500 million project to boost its R&D offering. Tuesday, December 13, 2016 It seems that president elect Donald Trump wants an investor as the next FDA commissioner, as Dr. Scott Gottlieb, a partner at one of the world's largest venture capital funds, is also now rumored by Reuters to be on his short list for the top job. Tuesday, December 13, 2016 Shares in Achaogen more than doubled after the company reported its lead drug—an antibiotic for serious multidrug resistant infections—met its targets in late-stage trials. Tuesday, December 13, 2016 Chicago-based biotech Exicure just signed its first partnership deal, with Purdue Pharma offering up to $790 million for rights to its lead psoriasis drug and three other projects. Tuesday, December 13, 2016 Lumendi is developing devices to shift invasive gastrointestinal surgeries toward minimally invasive endoluminal procedures—that is, procedures done entirely from within the intestine. The devicemaker earned FDA clearance for its endoscope stabilizer that facilitates endoluminal treatments. Monday, December 12, 2016 Cancer vaccines are making a comeback, and Pfizer has signed on with a startup in the field. The drug giant will back Ignite Immunotherapy's efforts to combine its own candidates with checkpoint inhibitors for a one-two punch against the disease. | | | Soligenix has has priced $5.27 million in a public offering as it completes its listing on the Nasdaq. Release Centrexion Therapeutics said it has seen some "highly statistically significant" data from its midstage test of CNTX-4975 in those with knee osteoarthritis pain. Statement Proteon Therapeutics plummeted 70% today on news that its late-stage study of vonapanitase flopped in certain kidney disease patients. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA Precision LBx Summit: Translating Next Generation Liquid Biopsies into Clinical Reality January 30-February 1, 2017 | San Diego, CA DeviceTalks December 12, 2016 | Newport Beach, CA Drug Development Boot CampTM 2017 November 15-16, 2017 | Boston, MA CBI’s IISR 2017 Summit February 14-15, 2017 | Philadelphia, PA | 